edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.
Kazia Therapeutics — 9 videos in collection
In the third part of our Edison TV series on Kazia Therapeutics (KZIA), John Friend, CMO, and James Garner, CEO, discuss the company’s second pipeline asset, EVT801. EVT801 is a small molecule inhibitor of VEGFR3, which preclinical data have shown to be active against a broad range of tumour types and provided compelling evidence of synergy with immunoncology agents.
Additionally, Karen Krumeich, CFO, discusses Kazia’s focus on increasing awareness of the company in the US capital markets. 2022 is a data-rich year for Kazia and this episode concludes with an overview of the anticipated milestones and catalysts.
Get access to the very latest content matched to your personal investment style.